Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.

Vetoquinol SA

Vetoquinol is an independent, family-owned business that develops, produces, and markets veterinary pharmaceuticals and health products for animals. Self-described commitment to values and a close relationship with veterinary clients.

EURONEXT:VETO

Vetoquinol

Last Close

85.30

25/09 14:21

Market Cap

1.14B

Beta: 0.83

Volume Today

1.35K

Avg: 3.08K

PE Ratio

25.79

PFCF: 30.67

Dividend Yield

0.76%

Payout:19.72%

locale

market

industry

website

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics